Comparison of the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor positive (HR+) postmenopausal women: The UK perspective

被引：0

作者：

Karnon, Jonathan

Delea, Thomas

Papo, Natalie L.

Barghout, Victoria

机构：

[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England

[2] Policy Anal Inc, Brookline, MA USA

[3] Novartis Pharmaceut UK Ltd, Frimley, England

[4] Novartis Pharmaceut Corp, E Hanover, NJ USA

来源：

ANNALS OF ONCOLOGY | 2006年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：107 / 107

页数：1

共 50 条

[21] Cost analysis of treatment-related adverse events with anastrozole (Arimidex) versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
Simons, R
Bassi, R
Jones, D
Barrett-Lee, P
[J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S131 - S131
[22] Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR plus early-stage breast cancer
Lipsitz, Michael
Delea, Thomas E.
Guo, Amy
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (10) : 2315 - 2328
[23] A cost-effectiveness analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with early-stage breast cancer in Mexico
Mould-Quevedo, J.
Tapia-Valencia, J.
Davila-Loaiza, G.
[J]. VALUE IN HEALTH, 2007, 10 (03) : A124 - A125
[24] International comparison of the cost-effectiveness of 5 years letrozole or anastrozole compared to 5 years tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Belgium, Canada, UK, and US analyses
Kaura, S.
Karnon, J.
di Trapani, F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[25] Applying survival based cost-effectiveness analyses to estimate the impact of patent expiry on the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer
Karnon, J.
Kaura, S.
[J]. EJC SUPPLEMENTS, 2010, 8 (03): : 66 - 66
[26] Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): A UK National Health Service (NHS) perspective
Benedict, A
[J]. VALUE IN HEALTH, 2004, 7 (03) : 221 - 221
[27] COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1-98 AND ATAC TRIALS: A UK PERSPECTIVE
Karnon, J.
Kaura, S.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
[28] COST-EFFECTIVENESS OF ANASTROZOLE, IN COMPARISON WITH TAMOXIFEN, IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL
Fonseca, Marcelo
Araujo, Gabriela T. B.
Saad, Everardo D.
[J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (04): : 410 - 415
[29] A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE
El Ouagari, K.
Kaura, S.
Karnon, J. D.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A279 - A279
[30] COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
Rudakova, A., V
[J]. VALUE IN HEALTH, 2009, 12 (07) : A276 - A276

← 1 2 3 4 5 →